NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Clinical trials for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged cancer therapy aims to outsmart relapsed lymphoma
Disease control Recruiting nowThis study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug duo aims to tame resistant blood cancers
Disease control Recruiting nowThis study is testing if adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and can help control several types of lymphoma that have returned or resisted standard chemotherapy. It is for adults with specific T-cell or B-cell lymphomas who have tried at least o…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New 'Living Drug' trial offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing a one-time treatment called MB-CART19.1, which uses a patient's own modified immune cells, in adults whose non-Hodgkin lymphoma has returned or not improved with standard therapies. The main goal is to see if this cell therapy can shrink or eliminate the can…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for tough lymphomas: first human trial begins
Disease control Recruiting nowThis is the first study in people testing a new drug called LTZ-301 for adults with non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also c…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC